Clinical trial
Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or…
NCT00019825 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00019825 |
|---|---|
| Title | Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura |
| Official title | Phase I Study of Decitabine Mediated Induction of Tumor Antigen and Tumor Suppressor Gene Expression in Lung Cancer Patients |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Esophageal Cancer, Lung Cancer, Malignant Mesothelioma, Metastatic Cancer |
| Intervention type | Drug |
| Interventions | decitabine |
| Start date | Oct 1, 1999 |
| First posted | Jan 27, 2003 |
| Last update posted | Apr 29, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: